PD-1 Blockers. Academic Article uri icon

Overview

abstract

  • Nivolumab and pembrolizumab are monoclonal antibodies that block the programmed death-1 receptor (PD-1, CD279), resulting in dis-inhibition of tumor-specific immune responses. Both are recently approved for use in the treatment of metastatic melanoma, and nivolumab as well for non-small cell lung cancer.

publication date

  • August 27, 2015

Research

keywords

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Melanoma
  • Programmed Cell Death 1 Receptor
  • Skin Neoplasms

Identity

Scopus Document Identifier

  • 84940403833

Digital Object Identifier (DOI)

  • 10.1016/j.cell.2015.07.045

PubMed ID

  • 26317459

Additional Document Info

volume

  • 162

issue

  • 5